Get the Stockscreener App
3.70
2.63%
-0.10
After Hours:
3.68
-0.02
-0.54%
Cingulate Inc stock is traded at $3.70, with a volume of 186.02K.
It is down -2.63% in the last 24 hours and up +0.00% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$3.80
Open:
$3.8
24h Volume:
186.02K
Relative Volume:
1.11
Market Cap:
$20.03M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1135
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-9.98%
1M Performance:
+0.00%
6M Performance:
-12.74%
1Y Performance:
-17.59%
1-Day Range:
$3.66
$3.88
1-Week Range:
$3.66
$4.40
52-Week Range:
$3.02
$6.01
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.70 | 21.30M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Backtesting results for Cingulate Inc. Equity Warrant trading strategiesInsider Selling & Stepwise Trade Execution Plans - newser.com
Can Cingulate Inc. stock deliver consistent earnings growthJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Will Cingulate Inc. stock gain from government policies2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
What institutional flow reveals about Cingulate Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
Will Cingulate Inc. stock remain a Wall Street favoriteTrade Signal Summary & Safe Entry Zone Identification - newser.com
Using portfolio simulators with Cingulate Inc. Equity Warrant includedTrade Entry Report & Entry Point Strategy Guides - newser.com
How Cingulate Inc. stock compares to industry benchmarksTrade Risk Assessment & High Conviction Buy Zone Alerts - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock bottoming outJuly 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success - TipRanks
How supply chain issues affect Cingulate Inc. stock2025 Investor Takeaways & Expert Verified Movement Alerts - newser.com
Why Cingulate Inc. stock could be next big winnerJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Does Cingulate Inc. fit your quant trading modelMarket Rally & Smart Investment Allocation Tips - newser.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review Retail Bets On Buyout Potential - Menafn.com
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - Asianet Newsable
Will Cingulate Inc. continue its uptrendJuly 2025 Earnings & Long-Term Safe Return Strategies - newser.com
FDA accepts Cingulate’s ADHD drug application, sets May 2026 target date - Investing.com Canada
What’s next for Cingulate Inc. stock priceJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Cingulate receives target date for when it could receive FDA approval - The Business Journals
Cingulate Inc’s NDA for CTx-1301 Accepted by FDA - TipRanks
Cingulate announces FDA accepted for review the NDA for CTx-1301 - TipRanks
Cingulate Inc FDA Accepts NDA for CTx-1301 for ADHD - TradingView
FDA Accepts Cingulate’s New Drug Application for CTx-1301 - GlobeNewswire
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date - Yahoo Finance
Will Cingulate Inc. bounce back from current support2025 Retail Activity & Verified Entry Point Signals - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
How Cingulate Inc. Equity Warrant stock trades before earningsWatch List & Daily Market Momentum Tracking - newser.com
Is it too late to sell Cingulate Inc.Quarterly Growth Report & AI Forecast for Swing Trade Picks - newser.com
Is Cingulate Inc a good long term investmentREITs Market Trends & Rapid Portfolio Strategies - earlytimes.in
Cingulate Inc. (NASDAQ:CING) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Is Cingulate Inc. stock entering bullish territoryCEO Change & Smart Money Movement Alerts - newser.com
Analyzing drawdowns of Cingulate Inc. Equity Warrant with statistical tools2025 Year in Review & Stock Timing and Entry Methods - newser.com
Market reaction to Cingulate Inc.’s recent newsDividend Hike & Consistent Income Trade Ideas - newser.com
Is Cingulate Inc. a candidate for recovery playInsider Selling & Weekly Chart Analysis and Guides - newser.com
Cingulate Inc. stock retracement – recovery analysisTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
What does recent volatility data suggest for Cingulate Inc.Trade Analysis Report & Verified Swing Trading Watchlist - newser.com
Using flow based indicators on Cingulate Inc.July 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):